Boston Scientific has reported net sales of $2.752bn in the first quarter of this year, representing a growth of 8.2% on a reported basis, compared to $2.543bn in the same quarter last year.
During the quarter, the company’s reported GAAP net income available to common stockholders stood at $327m, against $11m a year ago.
Boston Scientific chairman and CEO Mike Mahoney said: “We are pleased by the trajectory of our recovery.
“Our global team remains committed to helping patients and our customers by delivering a robust portfolio of innovative solutions, and that commitment will continue to fuel our future growth.”
The company achieved net sales growth of 11.1% reported in the MedSurg segment compared to the prior-year period.
In the Rhythm and Neuro segment net sales growth stood at 6.8% reported, while in the Cardiovascular segment it stood at 10% reported.
In the US and Europe, Middle East and Africa (EMEA) regions, the company achieved net sales growth of 8.6% and 9.4% reported, respectively.
Asia-Pacific region net sales for the quarter stood at 15.6% reported, and 16% reported was achieved in Emerging Markets.
The company’s recent developments include receipt of US Food and Drug Administration (FDA) approval for the TheraSphere Y-90 Glass Microspheres to treat hepatocellular carcinoma and FDA Breakthrough Device designation for TheraSphere treatment for glioblastoma patients.
It also received Japan’s Ministry of Health, Labor and Welfare approval for the Ranger Drug-Coated Balloon.
Last month, Boston Scientific bought Israeli medtech Lumenis’s surgical portfolio in a £1.07bn cash deal.
Other developments during the quarter included the launch of the Vercise Genus Deep Brain Stimulation (DBS) System and commencement of the WaveWriter Alpha portfolio of spinal cord stimulator (SCS) systems roll out, both in the US.